Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01297322
Other study ID # PTL 0243
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2011
Est. completion date July 2012

Study information

Verified date January 2020
Source Cardiva Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this trial is to demonstrate the safety and effectiveness of the Cardiva VASCADE™ Vascular Closure System (VCS) in sealing femoral arterial access sites. Hypothesis: The Cardiva VASCADE™ VCS provides times to hemostasis (TTH) and time to ambulation (TTA) results that are less than manual compression by a clinically meaningful and statistically significant margin. The rate of major access site-related complications with the Cardiva VASCADE™ VCS is non-inferior to the major complication rates of manual compression for sealing femoral arterial access sites.


Description:

A prospective, randomized, controlled multi-center clinical trial designed to evaluate the safety and effectiveness of the study device in sealing femoral arterial access sites and providing reduced times to hemostasis and ambulation compared with manual compression at the completion of diagnostic or interventional endovascular procedures performed through 6 Fr or 7 Fr introducer sheaths. Subjects will be randomized in a 2:1 treatment device to control ratio.


Recruitment information / eligibility

Status Completed
Enrollment 420
Est. completion date July 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Pre-Operative Inclusion Criteria:

- Patients undergoing an elective, non-emergent diagnostic or interventional endovascular procedure via the common femoral artery using a 6 or 7 Fr introducer sheath

Pre-Operative Exclusion Criteria:

1. Advanced refusal of blood transfusion, if necessary;

2. Active systemic or a cutaneous infection or inflammation;

3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;

4. Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's disease or current platelet count < 100,000 cells/mm3, baseline INR =1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours);

5. Severe co-existing morbidities having a life expectancy of less than 30 days;

6. Currently involved in any other investigational clinical trial;

7. Ipsilateral femoral arteriotomy within the previous 30 days;

8. Planned endovascular procedure within the next 30 days;

9. Previous ipsilateral femoral artery closure using a permanent implant-based closure device;

10. Previous vascular grafts or surgery at the target vessel access site;

11. History of symptomatic peripheral arterial disease, revascularization or deep vein thrombosis in the ipsilateral limb;

12. Unilateral or bilateral lower extremity amputation(s);

13. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than 30%;

14. Renal insufficiency (serum creatinine of > 2.5 mg/dl);

15. Females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating;

16. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20 kg/m2);

17. Unable to routinely walk at least 20 feet without assistance (see protocol);

18. Known allergy/adverse reaction to bovine derivatives, sodium hyaluronate or hyaluronan preparations;

19. Procedures that extend hospitalization (e.g., staged endovascular procedure, CABG);

20. Administration of low molecular weight heparin (LMWH) within 8 hours of the procedure.

Intra-op Exclusion Criteria

1. An introducer sheath with an overall length greater than 11 cm, or not 6 Fr or 7 Fr diameter;

2. Femoral artery diameter less than 6 mm at access site;

3. Difficult insertion of procedural sheath or needle stick problems at the onset of the procedure (e.g., multiple stick attempts, "back wall stick", etc.);

4. Angiographic evidence of more than minimal calcium, atherosclerotic disease, or stent within 1 cm of the puncture site;

5. Overlapping Common Femoral Vein and Femoral Artery at access site;

6. Placement of ipsilateral venous sheath during procedure;

7. Arterial access site located not at common femoral artery (e.g., on or below the bifurcation, above the lower border of the inferior epigastric artery, or above the pelvic brim);

8. More than one access site required;

9. Loss of distal pulses in the ipsilateral extremity during the procedure;

10. Subjects receiving unfractionated heparin with an ACT greater than 300 seconds in the absence of a glycoprotein IIb/IIIa inhibitor or greater than 250 seconds in the presence of a glycoprotein IIb/IIIa inhibitor (may wait to remove introducer sheath until ACT level reaches the target value);

11. Intra-procedural bleeding around sheath, or suspected intraluminal thrombus, hematoma, pseudoaneurysm, or AV fistula;

12. Systemic hypertension (BP greater than 180/110 mmHg) or hypotension (BP less than 90/60 mmHg) prior to randomization;

13. Length of the tissue tract, the distance between the anterior arterial wall and skin, is estimated to be less than 2.5 cm;

14. If the physician deems that a different method should be used to achieve hemostasis of the arterial site or that the subject should not attempt ambulation according to the protocol requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Manual compression
Standard of Care
Device:
Cardiva VASCADE™ Vascular Closure System
Investigational Hemostatic Vascular Closure System

Locations

Country Name City State
Australia St. Vincent's Hospital Melbourne Melbourne Victoria
United States King's Daughters Medical Center Ashland Kentucky
United States Heart Hospital of Austin Austin Texas
United States Tufts University Boston Massachusetts
United States Cooper Health System Camden New Jersey
United States CAMC Health Education and Research Institute, Inc. Charleston West Virginia
United States Thomas Hospital Fairhope Alabama
United States Terrebonne General Medical Center Houma Louisiana
United States St. Vincent's Heart Center of Indiana Indianapolis Indiana
United States Lafayette General Medical Center Lafayette Louisiana
United States Holmes Regional Medical Center Melbourne Florida
United States Winthrop University Hospital Mineola New York
United States New York-Presbyterian Hospital New York New York
United States Christiana Care Newark Delaware
United States Sentara Norfolk General Hospital Norfolk Virginia
United States Virginia Commonwealth University Medical Center Richmond Virginia
United States William Beaumont Hospital Royal Oak Michigan
United States St. John's Prairie Heart Springfield Illinois
United States Washington Adventist Hospital Takoma Park Maryland
United States Oklahoma Heart Institute Tulsa Oklahoma
United States Forsyth Medical Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Cardiva Medical, Inc.

Countries where clinical trial is conducted

United States,  Australia, 

References & Publications (8)

Castañeda F, Swischuk JL, Smouse HB, Brady T. Gelatin sponge closure device versus manual compression after peripheral arterial catheterization procedures. J Vasc Interv Radiol. 2003 Dec;14(12):1517-23. — View Citation

Gerckens U, Cattelaens N, Lampe EG, Grube E. Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device. Am J Cardiol. 1999 Jun 15;83(12):1658-63. — View Citation

Hoffer EK, Bloch RD. Percutaneous arterial closure devices. J Vasc Interv Radiol. 2003 Jul;14(7):865-85. Review. — View Citation

Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003 Oct 15;92(8):930-5. — View Citation

Kussmaul WG 3rd, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 Jun;25(7):1685-92. — View Citation

Lehmann KG, Heath-Lange SJ, Ferris ST. Randomized comparison of hemostasis techniques after invasive cardiovascular procedures. Am Heart J. 1999 Dec;138(6 Pt 1):1118-25. — View Citation

Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998 Apr 30;17(8):873-90. Erratum in: Stat Med 1999 May 30;18(10):1293. — View Citation

Simon A, Bumgarner B, Clark K, Israel S. Manual versus mechanical compression for femoral artery hemostasis after cardiac catheterization. Am J Crit Care. 1998 Jul;7(4):308-13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Hemostasis (TTH) Primary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and first observed and confirmed arterial hemostasis. Up to 1 hour
Primary Rate of Combined Access Site-related Major Complications Primary safety endpoint
Access site-related bleeding requiring transfusion;
Vascular injury requiring repair (via surgery, ultrasound guided compression, transcatheter embolization or stent graft);
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb and requiring surgical or additional percutaneous intervention. This compromised blood flow is documented by subject symptoms, physical exam and/or a decreased or absent blood flow on lower extremity angiogram.;
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization;
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair;
Permanent access site-related nerve injury. (> 30 days)
30 days +/- 7 days
Secondary Time to Ambulation (TTA) Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding Up to 1 day
Secondary Time to Discharge Eligibility (TTDE) Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is medically able to be discharged based solely on the assessment of the access site, as determined by the medical team Up to 2 days
Secondary Time to Hospital Discharge (TTHD) Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is actually discharged from the hospital Up to 2 days
Secondary Device Success Secondary effectiveness endpoint - ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with VASCADE alone or with adjunctive compression Up to 1 day
Secondary Procedure Success Secondary effectiveness endpoint - attainment of final hemostasis using any method and freedom from major vascular complications through 30 days 30 days +/- 7 days
Secondary Rate of Combined Minor Access Site Complications Secondary safety endpoint
Access site-related bleeding requiring greater than 30 minutes to achieve hemostasis;
Access site-related hematoma > 6 cm;
Late access site-related bleeding (following hospital discharge);
Ipsilateral lower extremity arterial emboli;
Ipsilateral deep vein thrombosis;
Access site-related vessel laceration;
Access site wound dehiscence;
Localized access site infection treated with intramuscular or oral antibiotics;
Arteriovenous fistula not requiring treatment;
Pseudoaneurysm requiring thrombin injection or fibrin adhesive injection;
Pseudoaneurysm not requiring treatment;
New onset access site-related neuropathy in the ipsilateral lower extremity not requiring surgical repair;
Ipsilateral pedal pulse diminished by two grades or transiently lost.
30 days +/- 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT02685761 - Skin Incisions and Wound Complication Rates for C-sections in Obese Women N/A
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Completed NCT03193021 - AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID N/A
Not yet recruiting NCT06028854 - Blood Characteristics and Abdominal Emergency Surgery
Completed NCT05646121 - Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT06342479 - Discharge Training for Patients With Intertrochanteric Fracture N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Recruiting NCT04994145 - A Post-Market Clinical Investigation on Mepilex Border Post-Op
Recruiting NCT04439552 - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Completed NCT04596163 - Transversus Thoracis Muscle Plane Block for Sternotomy Pain in Cardiac Surgery N/A
Completed NCT04036344 - Buddy Relationships in DermatoloGic Excisions for Skin Cancer N/A
Completed NCT05791721 - Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery Phase 4
Recruiting NCT06073678 - Photobiomodulation in Palate Wounds: Somatosensorial Evaluation N/A
Withdrawn NCT04053946 - Clinical Assessment of Next Science Wound Gels in Healing Below the Knee Amputation Surgical Wound Compared to SOC N/A
Completed NCT05252260 - Comparison of Diode Laser-Assisted Vestibuloplasty And Conventional Vestibuloplasty N/A
Recruiting NCT04740775 - LiquiBand® Exceed™ and LiquiBand® Rapid™ for General Surgery Procedures N/A
Terminated NCT04712019 - Evaluating Edema and Range of Motion Using Negative Pressure Therapy vs. Standard Surgical Dressing in Bilateral TKA N/A